A detailed history of Bank Of America Corp transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Bank Of America Corp holds 26,952 shares of PDSB stock, worth $56,329. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,952
Previous 45,035 40.15%
Holding current value
$56,329
Previous $131,000 22.14%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.93 - $4.23 $52,983 - $76,491
-18,083 Reduced 40.15%
26,952 $102,000
Q2 2024

Aug 14, 2024

SELL
$2.55 - $4.02 $95,339 - $150,299
-37,388 Reduced 45.36%
45,035 $131,000
Q1 2024

May 15, 2024

SELL
$3.85 - $6.59 $9,736 - $16,666
-2,529 Reduced 2.98%
82,423 $326,000
Q4 2023

Feb 14, 2024

BUY
$3.95 - $6.58 $203,535 - $339,054
51,528 Added 154.16%
84,952 $422,000
Q2 2023

Aug 14, 2023

SELL
$5.03 - $9.9 $57,241 - $112,662
-11,380 Reduced 25.4%
33,424 $168,000
Q1 2023

May 12, 2023

BUY
$5.68 - $11.99 $98,411 - $207,738
17,326 Added 63.05%
44,804 $275,000
Q4 2022

Feb 10, 2023

SELL
$3.28 - $13.2 $7,288 - $29,330
-2,222 Reduced 7.48%
27,478 $362,000
Q3 2022

Nov 14, 2022

SELL
$2.97 - $5.79 $94,538 - $184,301
-31,831 Reduced 51.73%
29,700 $88,000
Q2 2022

Aug 12, 2022

BUY
$3.05 - $6.68 $8,207 - $17,975
2,691 Added 4.57%
61,531 $224,000
Q1 2022

May 16, 2022

BUY
$4.78 - $8.43 $261,313 - $460,851
54,668 Added 1310.35%
58,840 $364,000
Q4 2021

Feb 08, 2022

BUY
$7.76 - $14.35 $31,924 - $59,035
4,114 Added 7093.1%
4,172 $34,000
Q3 2021

Nov 15, 2021

SELL
$9.33 - $17.08 $1,371 - $2,510
-147 Reduced 71.71%
58 $1,000
Q2 2021

Sep 13, 2021

BUY
$4.35 - $12.86 $891 - $2,636
205 New
205 $2,000

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $59.5M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.